|  |
1
|
2
|
3
|
4
|
6
|
---|
% positive
|
p vs PP
|
p vs NP
|
p vs COMB
|
p vs CENT
|
p vs EA
|
---|
H
| 0.43 | 0.67 | 0.847 | 1 | 0.286 | 0.015 |
I
| 0 | 1 | 1 | 1 | 0.197 | 1 |
J
| 0.07 | 1 | 1 | 1 | 1 | 0.243 |
K
| 0.04 | 1 | 1 | 1 | 0.677 | 0.184 |
NN
| 0.11 | 0.11 | 0.065 | 0.065 | ND | 1 |
T
| 0.11 | 1 | 1 | 1 | 1 | 1 |
U
| 0.25 | 0.62 | 0.29 | 0.31 | 0.053 | 1 |
V
| 0 | 0.22 | 0.629 | 0.389 | 1 | 1 |
W
| 0 | 1 | 0.614 | 1 | 1 | 0.227 |
X
| 0 | 1 | 1 | 1 | 1 | 1 |
- Haplogroup distribution in VSCC patients cohort was were compared with 1) the general Polish population (p vs PP) [38], 2) population from the Northern Poland (p vs NP) [39], 3) those two populations combined (p vs COMB), 4) cancer free centenarians cohort (p vs CENT), 5) head and neck tumors patients cohort (p vs HNC), and 6) endometrial adenocarcinoma patients cohort (p vs EA) [11]. % positive - percentage of patients carrying particular haplotype in VSCC cohort. Significant differences - bolded: O - overrepresented in VSCC cohort, U - underrepresented in VSCC cohort.